Primary Biliary Cirrhosis (PBC) Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32)- Asserts DelveInsight | Ascletis, Calliditas, Cour Pharma, CymaBay, Genfit, Novartis

Primary Biliary Cirrhosis (PBC) Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32)-  Asserts DelveInsight | Ascletis, Calliditas, Cour Pharma, CymaBay, Genfit, Novartis
Delveinsight Business Research LLP
Primary Biliary Cirrhosis Market size in the 7MM was USD 900 million in 2021, which is expected to grow by 2032. As per DelveInsight, the Primary Biliary Cirrhosis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Primary Biliary Cirrhosis and the launch of new therapies in the market.

DelveInsight’s “Primary Biliary Cirrhosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Biliary Cirrhosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Primary Biliary Cirrhosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Primary Biliary Cirrhosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Primary Biliary Cirrhosis: An Overview

Primary Biliary Cirrhosis (PBC), now known as primary biliary cholangitis, is an autoimmune disorder that leads to the gradual destruction of intrahepatic bile ducts resulting in periportal inflammation, and cholestasis. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension.

Primary Biliary Cirrhosis is the most common cholestatic disease of middle-aged women in the United States. Researchers theorize that patients with Primary Biliary Cirrhosis have both genetic predispositions with the right environmental trigger. The prevalence of the disease is 100-fold higher in first-degree relatives of the index patient, which strongly suggests a genetic predisposition.

Patients with Primary Biliary Cirrhosis can be asymptomatic or may present with jaundice, pruritus, and fatigue. Asymptomatic patients are incidentally diagnosed when they are found to have abnormal liver chemistry during evaluation for some other cause. The prevalence of Primary Biliary Cirrhosis has shown a consistent increase in the last two decades in epidemiological studies across different geographies. This increase has been reported up to 50% in some United States studies and a ~30% increase in Europe

Primary Biliary Cirrhosis Market Key Facts

  • The total diagnosed prevalent population of primary biliary cholangitis in the 7MM countries was estimated to be approximately 253,000+ cases in 2021.

  • Among the European countries, Germany had the highest population of Primary Biliary Cirrhosis with around 32,000 cases, followed by the UK, which had around 25,000+ cases in 2021. On the other hand, France had the lowest Primary Biliary Cirrhosis population, with around 11,900+ cases in 2021.

  • The prevalent population of Primary Biliary Cirrhosis in Japan was approximately 46,000+ cases in 2021.

  • Among the EU5 countries, France had the lowest prevalent population, with around 11,900+ cases in 2021.

Primary Biliary Cirrhosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Primary Biliary Cirrhosis pipeline therapies. It also thoroughly assesses the Primary Biliary Cirrhosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Primary Biliary Cirrhosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Primary Biliary Cirrhosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Primary Biliary Cirrhosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Primary Biliary Cirrhosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Primary Biliary Cirrhosis Epidemiology, Segmented as –

  • Total diagnosed prevalent cases of Primary Biliary Cholangitis [2019–2032]

  • Gender-specific cases of Primary Biliary Cholangitis [2019–2032]

  • Age-specific cases of Primary Biliary Cholangitis [2019–2032]

Primary Biliary Cirrhosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Primary Biliary Cirrhosis market or expected to be launched during the study period. The analysis covers the Primary Biliary Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Primary Biliary Cirrhosis drugs based on their sale and market share.

The report also covers the Primary Biliary Cirrhosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Primary Biliary Cirrhosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Primary Biliary Cirrhosis Market Will Evolve and Grow by 2032 @

Primary Biliary Cirrhosis Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Primary Biliary Cirrhosis. Currently, Genfit is leading the therapeutics with its Primary Biliary Cirrhosis drug candidates in the most advanced stage of clinical development.

The Leading Players in the Primary Biliary Cirrhosis Therapeutics Market Include:

  • Ascletis

  • Calliditas Therapeutics

  • Chia Tai Tianqing Pharmaceutical Group

  • Cour Pharmaceutical Development

  • CymaBay Therapeutics

  • Genfit

  • GlaxoSmithKline

  • HighTide Biopharma

  • Intercept Pharmaceuticals

  • Mirum Pharmaceuticals

  • Novartis

  • PRISM Pharma Co

  • Zydus-Cadila

And Many More

Primary Biliary Cirrhosis Emerging and Marketed Drugs Covered in the Report Include:

  • Elafibranor: Genfit

  • Seladelpar: CymaBay Therapeutics

  • Setanaxib: Calliditas Therapeutics

And Many Others

The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Primary Biliary Cirrhosis Competitive Intelligence Analysis

4. Primary Biliary Cirrhosis Market Overview at a Glance

5. Primary Biliary Cirrhosis Disease Background and Overview

6. Primary Biliary Cirrhosis Patient Journey

7. Primary Biliary Cirrhosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Primary Biliary Cirrhosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Biliary Cirrhosis Unmet Needs

10. Key Endpoints of Primary Biliary Cirrhosis Treatment

11. Primary Biliary Cirrhosis Marketed Therapies

12. Primary Biliary Cirrhosis Emerging Drugs and Latest Therapeutic Advances

13. Primary Biliary Cirrhosis Seven Major Market Analysis

14. Attribute Analysis

15. Primary Biliary Cirrhosis Market Outlook (In US, EU5, and Japan)

16. Primary Biliary Cirrhosis Companies Active in the Market

17. Primary Biliary Cirrhosis Access and Reimbursement Overview

18. KOL Views on the Primary Biliary Cirrhosis Market

19. Primary Biliary Cirrhosis Market Drivers

20. Primary Biliary Cirrhosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Elevating Cancer Care: DelveInsight’s specialized oncology consulting empowers with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore further at Oncology Consulting Services.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States